{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T13:47:02Z","timestamp":1794836822066,"version":"4.9.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,3,20]],"date-time":"2018-03-20T00:00:00Z","timestamp":1521504000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ital J Pediatr"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13052-018-0469-x","type":"journal-article","created":{"date-parts":[[2018,4,4]],"date-time":"2018-04-04T00:24:47Z","timestamp":1522801487000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Dolutegravir-based anti-retroviral therapy is effective and safe in HIV\u2013infected paediatric patients"],"prefix":"10.1186","volume":"44","author":[{"given":"Eugenia","family":"Bruzzese","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Lo Vecchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Smarrazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orsola","family":"Tambaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Palmiero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Bonadies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Guarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,20]]},"reference":[{"key":"469_CR1","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.jadohealth.2010.03.013","volume":"47","author":"PA Garvie","year":"2010","unstructured":"Garvie PA, Wilkins ML, Young JC. Medication adherence in adolescents with behaviorally-acquired HIV: evidence for using a multimethod assessment protocol. J Adolesc Health. 2010;47:504\u201311.","journal-title":"J Adolesc Health"},{"key":"469_CR2","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1111\/j.1651-2227.2003.tb00822.x","volume":"92","author":"V Giacomet","year":"2003","unstructured":"Giacomet V, Albano F, Starace F, de Franciscis A, Giaquinto C, Gattinara GC, et al. Adherence to antiretroviral therapy and its determinants in children with human immunodeficiency virus infection: a multicentre, national study. Acta Paediatr. 2003;92:1398\u201340.","journal-title":"Acta Paediatr"},{"key":"469_CR3","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1080\/09540120600909406","volume":"19","author":"F Albano","year":"2007","unstructured":"Albano F, Giacomet V, De Marco G, Bruzzese E, Starace F, Guarino A. Adherence to antiretroviral therapy in children: a comparative evaluation of caregiver reports and physician judgement. AIDS Care. 2007;19:764\u20136.","journal-title":"AIDS Care"},{"key":"469_CR4","unstructured":"Guidelines for the use of antiretroviral agents in pediatric HIV infection (2016), http:\/\/aidsinfo.nih.gov\/guidelines. Accessed 3 Mar 2017."},{"key":"469_CR5","unstructured":"Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents (2016), http:\/\/aidsinfo.nih.gov\/guidelines. Accessed 3 Mar 2017."},{"key":"469_CR6","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1177\/1060028013513558","volume":"48","author":"RC Rathbun","year":"2014","unstructured":"Rathbun RC, Lockhart SM, Miller MM, Liedtke MD. Dolutegravir, a second-generation integrase inhibitor for the treatment of HIV-1 infection. Ann Pharmacother. 2014;48:395\u2013403.","journal-title":"Ann Pharmacother"},{"issue":"11","key":"469_CR7","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1097\/INF.0000000000000848","volume":"34","author":"RM Viani","year":"2015","unstructured":"Viani RM, Alvero C, Fenton T, Acosta EP, Hazra R, Townley E, et al. Safety, pharmacokinetics and efficacy of dolutegravir in treatment-experienced HIV-1 infected adolescents: 48-week results from IMPAACT P1093. Pediatr Infect Dis J. 2015;34(11):1207\u201313. \n                    https:\/\/doi.org\/10.1097\/INF.0000000000000848\n                    \n                  .","journal-title":"Pediatr Infect Dis J"},{"key":"469_CR8","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1007\/s40265-014-0256-y","volume":"74","author":"MC PL","year":"2014","unstructured":"PL MC. Dolutegravir: a review of its use in the management of HIV-1 infection in adolescents and adults. Drugs. 2014;74:1241\u201352.","journal-title":"Drugs"},{"key":"469_CR9","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1097\/QAD.0000000000000696","volume":"29","author":"G Bonadies","year":"2015","unstructured":"Bonadies G, Maraolo AE, Tambaro O, Palmiero G, Di Filippo G, Orlando R. Dolutegravir: successful experience in a challenging patient. AIDS. 2015;29:1269\u201371.","journal-title":"AIDS"},{"key":"469_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nmni.2015.02.003","volume":"6","author":"N Wagner","year":"2015","unstructured":"Wagner N, Wyler-Lazarevic CA, Yerly S, Samer C, Peytavin G, Posfay-Barbe KM, et al. Dolutegravir-based antiretroviral therapy in a severely overweight child with a multidrug-resistant human immunodeficiency virus infection. A case report and review. New Microbes New Infect. 2015;6:1\u20134.","journal-title":"New Microbes New Infect"},{"issue":"18","key":"469_CR11","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1097\/QAD.0000000000000888","volume":"29","author":"C Pinnetti","year":"2015","unstructured":"Pinnetti C, Tintoni M, Ammassari A, Tamburrini E, Bernardi S, Liuzzi G, et al. Successful prevention of HIV mother-to-child transmission with dolutegravir-based combination antiretroviral therapy in a vertically infected pregnant woman with multiclass highly drug-resistant HIV-1. AIDS. 2015. Nov 28;29(18):2534\u20137.","journal-title":"AIDS"},{"key":"469_CR12","unstructured":"Centers for Disease Control and Prevention (CDC). Revised surveillance case definition for HIV infection \u2014 United States, vol. Vol. 63 \/ No. 3: MMWR 2014. Recommendations and reports; 2014."},{"key":"469_CR13","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1093\/infdis\/jiu051","volume":"210","author":"A Castagna","year":"2014","unstructured":"Castagna A, Maggiolo F, Penco G, Wright D, Mills A, Grossberg R, et al. Viking-3 study group. Dolutegravir in antiretroviral experienced patients. J Infect Dis. 2014;210:354\u201362.","journal-title":"J Infect Dis"},{"key":"469_CR14","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1186\/1741-7015-11-249","volume":"11","author":"MA Wainberg","year":"2013","unstructured":"Wainberg MA. Mesple\u2019de T, Raffi F. What if HIV were unable to develop resistance against a new therapeutic agent? BMC Med. 2013;11:249.","journal-title":"BMC Med"},{"key":"469_CR15","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1016\/S0140-6736(14)60084-2","volume":"383","author":"B Clotet","year":"2014","unstructured":"Clotet B, Feinberg J, van Lunzen J, Khuong-Josses MA, Antinori A, Dumitru I, et al. ING114915 study team. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48-week results from the randomised open-label phase 3b study. Lancet. 2014;383:2222\u201331.","journal-title":"Lancet"},{"issue":"12","key":"469_CR16","doi-asserted-by":"publisher","first-page":"e547","DOI":"10.1016\/S2352-3018(17)30152-2","volume":"4","author":"I Wijting","year":"2017","unstructured":"Wijting I, Rokx C, Boucher C, van Kampen J, Pas S, de Vries-Sluijs T, et al. Dolutegravir as maintenance monotherapy for HIV (DOMONO): a phase 2, randomised non-inferiority trial. Lancet HIV. 2017;4(12):e547\u201354.","journal-title":"Lancet HIV"},{"key":"469_CR17","unstructured":"Joly V, Burdet C, Landman R, Raffi F, Katlama C, Cabi\u00e9 A et al. Promising results of dolutegravir + lamivudine in ANRS 167 LAMIDOL trial. presented at: conference on retroviruses and opportunistic infections (CROI 2017); 13\u201316 February, 2017; Seattle, WA, USA. Abstract 458."},{"key":"469_CR18","unstructured":"M. Aboud, R. Kaplan, J. Lombaard, F. Zhang, J. Hidalgo, E. Mamedova et al. Superior efficacy of dolutegravir (DTG) plus 2 nucleoside reverse transcriptase inhibitors (NRTIs) compared with lopinavir\/ritonavir (LPV\/RTV) plus 2 NRTIs in second-line treatment: interim data from the DAWNING study. Presented at: 9th IAS Conference on HIV Science (IAS 2017); 23\u201326 July, 2017; Paris, France. Abstract TUAB0105LB."}],"container-title":["Italian Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13052-018-0469-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13052-018-0469-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13052-018-0469-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,19]],"date-time":"2019-03-19T20:05:29Z","timestamp":1553025929000},"score":1,"resource":{"primary":{"URL":"https:\/\/ijponline.biomedcentral.com\/articles\/10.1186\/s13052-018-0469-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,20]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["469"],"URL":"https:\/\/doi.org\/10.1186\/s13052-018-0469-x","relation":{},"ISSN":["1824-7288"],"issn-type":[{"value":"1824-7288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,20]]},"assertion":[{"value":"28 September 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"No ethical committee opinion was requested because the use of this drug in adolescents is suggested by international guidelines. All procedures performed in this study were in accordance with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. An informed consent for the sharing of anonymous patient data was obtained from families and\/or caregivers.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"37"}}